Every peptide founder eventually learns the same lesson, usually the expensive way: in this industry, the question isn’t which payment method is best. It’s what happens to your revenue on the day one of them stops working.
A card account under review. A PayPal balance frozen mid-month. A gateway outage during your biggest promotion. Run everything on a single rail and any one of those events takes your revenue to zero — not eventually, but that afternoon.
So this comparison of ACH, credit cards, and digital wallets isn’t a beauty contest with one winner. By the end, you’ll know the real cost and conversion profile of each rail, which digital wallets are safe for peptide merchants and which are traps, and how to combine them into a stack — with the actual dollar math on what that stack saves.
Credit Cards: The Conversion Engine
Cards are where your customers already are. Worldpay’s Global Payments Report puts credit and debit cards at roughly half of North American e-commerce spend, with digital wallets taking most of the remainder. If you sell online, cards are the default expectation — remove them and watch conversion fall off a cliff.
The trade-offs are the ones this industry knows well. Peptide merchants pay high-risk card rates — typically 3.5–6% all-in, plus reserves — which we’ve broken down line by line in our guide to peptide payment processing costs. Cardholders get a dispute window of roughly 120 days, so chargebacks are a permanent operating condition. And access requires underwriting: see our peptide merchant account approval guide for how to get boarded in days instead of weeks.
Verdict: non-negotiable for consumer conversion, expensive by design, and never the rail to run alone.
ACH: The Margin and Resilience Rail
ACH — bank-to-bank transfer, often labeled “e-check” at checkout — is the most underused rail in the peptide space, and the numbers explain why it shouldn’t be.
Cost: high-risk ACH typically runs 1–2%, or even a flat fee per transaction, against 4.5%+ on cards. On a $250 order, that’s the difference between paying about $3 and paying about $11 to move the same money.
No card networks: ACH transactions never touch Visa or Mastercard, so there’s no card-brand registration, no chargeback ratio feeding a monitoring program. ACH has its own referee instead — NACHA — with its own concrete thresholds: unauthorized return rates must stay under 0.5%, administrative returns under 3%, and total returns under 15%. Cleaner rules, and for a well-run merchant, easier ones.
Disputes exist, but differently: consumers can dispute unauthorized ACH debits, generally within 60 days under Regulation E. What mostly comes back instead are R01s — insufficient funds — which is why ACH pairs well with account-verification at checkout.
The catches: standard settlement takes 3–5 business days (same-day ACH exists, capped at $1 million per payment), and asking a first-time customer to type a routing number costs you conversion. More on that objection below.
Verdict: dramatically cheaper, structurally insulated from card-network risk, slower — and the single best second rail a peptide business can add.
Digital Wallets: Two Very Different Animals
“Digital wallets” covers two categories that could not be more different for this industry, and confusing them is costly.
Apple Pay and Google Pay: cards in a better suit
These wallets ride card rails through your existing merchant account. Same pricing, same rules — but tokenized credentials and biometric approval cut fraud, and one-tap mobile checkout lifts conversion where peptide stores need it most: the phone. If your high-risk gateway supports them — Great West Pay enables both on peptide merchant accounts — turning them on is a conversion upgrade with no new risk category attached.
PayPal, Venmo, and Cash App: the freeze machines
Consumer P2P wallets are a different story. Their acceptable-use policies place research chemicals and pseudo-pharmaceutical products in prohibited territory, and their enforcement pattern is the one this series keeps warning about: the account works until a review notices the catalog, then the balance freezes — commonly for 180 days. Every month of “it’s been fine so far” just raises the size of the balance that gets locked.
A brief word on crypto, since peptide merchants ask: it eliminates chargebacks, but it also eliminates most of your buyers — adoption at checkout remains a small fraction of card volume — and adds its own compliance overhead. Treat it as an optional third rail for the customers who ask, never a foundation.
Verdict: Apple Pay and Google Pay, yes — through your merchant account. Consumer P2P wallets, no — at any volume you can’t afford to lose for six months.
The Stack in Practice
Here’s what the combination is worth, on a merchant doing $60,000 a month.
All-cards at 4.5%, processing costs about $2,700 monthly. Now shift 30% of volume — $18,000, mostly repeat customers and larger bulk orders — to ACH at 1%. Those orders now cost $180 instead of $810 to process. That’s $630 a month back, roughly $7,500 a year, for adding a checkout option.
Getting customers to choose ACH is simpler than it sounds: fund an incentive from the fee spread. Offer a 3% discount on ACH orders — you still net more than you would on the card rate — and frame it exactly that way. An ACH discount is compliant everywhere; a card surcharge triggers card-brand caps (Visa’s sits at 3%) and a patchwork of state rules. Same economics, very different rulebook.
And the savings are only half the case. The stack’s real value shows up on the bad day: if your card account ever goes under review, ACH keeps revenue flowing while you resolve it. That’s the pattern Great West Pay builds toward with peptide merchants — cards plus ACH from day one, wallets on top — because the businesses that survive in this category are the ones a single freeze can’t switch off.
“Nobody Types a Routing Number” — the Conversion Objection
Fair. Raw ACH checkout — find your checkbook, copy nine digits — converts poorly with first-time buyers, and no discount fully fixes that.
Three things change the math. Instant bank-login verification (Plaid-style connections) replaces routing-number entry with a two-tap bank login. Repeat buyers — the backbone of peptide revenue — will happily save 3% on a purchase they make monthly; ACH adoption concentrates exactly where your volume does. And bulk or B2B orders, where tickets are largest and card fees hurt most, already expect bank payment as normal practice.
You’re not converting strangers to ACH. You’re converting your tenth-order customers — and they’re the cheapest customers to convince.
The short version: Cards are mandatory for conversion and priced accordingly; run them through a proper high-risk account. ACH costs 1–2% instead of 4.5%+, answers to NACHA instead of Visa, and is the resilience rail — incentivize it with a compliant ACH discount. Apple Pay and Google Pay are safe conversion boosters on your merchant account; PayPal, Venmo, and Cash App are 180-day freezes waiting to happen. One rail is a single point of failure. Two is a business.
Redundancy Is a Feature You Buy Before You Need It
Ask any peptide founder who’s been through a freeze what they’d pay to have had a second rail running that morning. The answer is always more than the second rail costs.
Ask Great West Pay about a cards-plus-ACH setup for your peptide business — one application, both rails, Apple Pay and Google Pay included — at greatwestpay.com.
